SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Novozymes A/S (NVZMY) trades at a trailing P/E of 48.0, forward P/E of 3.9. Trailing earnings yield is 2.08%, forward earnings yield 25.38%. PEG 0.55 (Peter Lynch undervalued ≤1.0).
Criteria proven by this page:
- VALUE (15/100, Fail) — trailing P/E is well above the S&P 500 average of ~25, suggesting a premium valuation (P/E 48.0).
- Forward P/E 3.9 (down from trailing 48.0) — analysts expect earnings to grow, which would improve the valuation.
- PEG Ratio 0.55 — below 1.0 suggests the stock is undervalued relative to its earnings growth rate (Peter Lynch criterion).
- Trailing Earnings Yield 2.08% — below bond yields — investors are paying a premium for expected growth rather than current earnings. Forward yield improves to 25.38% as earnings recover.
Overall SharesGrow Score: 45/100 with 2/7 criteria passed.
SharesGrow 7-Criteria Score
✗
VALUE
15/100
Price-to-Earnings & upside
Proven by this page
✗
HEALTH
33/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — NVZMY
Valuation Multiples
P/E (TTM)48.0
Forward P/E3.9
PEG Ratio0.55
Forward PEG0.31
P/B Ratio0.00
P/S Ratio6.74
EV/EBITDA0.0
Per Share Data
EPS (TTM)$1.25
Forward EPS (Est.)$15.23
Book Value / Share$0.00
Revenue / Share$8.90
FCF / Share$0.00
Yields & Fair Value
Earnings Yield2.08%
Forward Earnings Yield25.38%
Dividend Yield0.00%
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2016 |
$10.06 |
$14.14B |
$3.05B |
21.6% |
| 2017 |
$10.49 |
$14.53B |
$3.12B |
21.5% |
| 2018 |
$11.03 |
$14.39B |
$3.23B |
22.4% |
| 2019 |
$11.01 |
$14.37B |
$3.15B |
21.9% |
| 2020 |
$10.02 |
$14.01B |
$2.83B |
20.2% |
| 2021 |
$11.23 |
$14.95B |
$3.15B |
21% |
| 2022 |
$13.19 |
$17.55B |
$3.68B |
20.9% |
| 2023 |
$10.88 |
$17.9B |
$3.02B |
16.9% |
| 2024 |
$0.67 |
$3.83B |
$305.8M |
8% |
| 2025 |
$1.25 |
$4.16B |
$583.6M |
14% |
